COST-EFFECTIVENESS AND CLINICAL IMPLICATIONS OF ADVANCED BEARINGS IN TOTAL KNEE ARTHROPLASTY: A LONG-TERM MODELING ANALYSIS

2014 ◽  
Vol 30 (2) ◽  
pp. 218-225 ◽  
Author(s):  
Peter Fennema ◽  
Thomas J. Heyse ◽  
Carin A. Uyl-de Groot
Keyword(s):  
Sensitivity Analysis ◽  
Total Knee Arthroplasty ◽  
Cost Effectiveness ◽  
Knee Arthroplasty ◽  
Probabilistic Sensitivity Analysis ◽  
Cost Effective ◽  
Total Knee ◽  
Low Wear ◽  
The Cost

Background:Polyethylene (PE) wear is a major contributor to implant loosening following total knee arthroplasty (TKA). Advanced bearings are therefore required in TKA to reduce or eliminate wear-related loosening. A recently introduced bearing that combines oxidized zirconium with highly cross-linked PE has been shown to drastically reduce wear inin vitrosettings, due to its improved tribological characteristics in both tibial and femoral components. However, there are no data on its cost-effectiveness.Data and Methods:A Markov model was developed to assess the cost-effectiveness of this low-wear bearing from a German societal perspective. The model population was derived from a registry of 75,000 patients requiring TKA. The model allocated patients to receive either a low-wear or standard articulation, and followed them until death. Revisions and re-revision were included. Input values were derived from registry databases or from published reports in the literature. Threshold analysis and probabilistic sensitivity analysis were conducted to estimate model robustness.Results:The low-wear articulation prevented 24 (2.4 percent) revisions and 8 (0.8 percent) re-revisions. The total incremental cost-effectiveness ratio (ICER) of the low-wear articulation was EUR 16,474 per quality-adjusted life-year (QALY). For patients aged less than 55 years, an ICER of EUR 653 per QALY was observed. For patients aged over 75 years, this value was EUR 83,300. Threshold and probabilistic sensitivity analysis indicated that these findings were reasonably robust.Conclusion:Low-wear articulations may be considered cost-effective, although the cost effectiveness is age-dependent, with the cost per QALY being significantly lower for younger people than for older people.

scholarly journals Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e038867 ◽  
Author(s):  
Wenxiu Xin ◽  
Haiying Ding ◽  
Qilu Fang ◽  
Xiaowei Zheng ◽  
Yinghui Tong ◽  
...  
Keyword(s):  
Sensitivity Analysis ◽  
Squamous Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Probabilistic Sensitivity Analysis ◽  
Cost Effective ◽  
Platinum Resistant ◽  
The Cost

BackgroundPembrolizumab was recently demonstrated to have survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma (r/mHNSCC). However, the cost-effectiveness of pembrolizumab versus chemotherapy in China remains uncertain.ObjectiveThis analysis aimed to describe the cost-effectiveness of pembrolizumab versus standard-of-care (SOC) therapy in r/mHNSCC in China.DesignA Markov model consisting of three health states (stable, progressive and dead) was developed to compare the cost and effectiveness of pembrolizumab with SOC in platinum-resistant r/mHNSCC. Model inputs for transition probabilities and toxicity were collected from the KEYNOTE-040 trial, while health utilities were estimated from a literature review. Cost data were acquired for the payer’s perspective in China. Costs and outcomes were discounted at an annual rate of 3.0%. Sensitivity analyses were conducted to test the uncertainties surrounding model parameters.Outcome measuresThe primary outcome was incremental cost-effectiveness ratios (ICERs), which were calculated as the cost per quality-adjusted life years (QALYs).ResultsThe total mean cost of pembrolizumab and SOC was US$45 861 and US$41 950, respectively. As for effectiveness, pembrolizumab yielded 0.31 QALYs compared with 0.25 QALYs for SOC therapy. The ICER for pembrolizumab versus SOC was US$65 186/QALY, which was higher than the willingness-to-pay threshold (WTP) of US$28 130/QALY in China. The univariate sensitivity analysis indicated that utility values for progressive state, probability from stable to progressive in the SOC group, as well as cost of pembrolizumab were the three most influential variables on ICER. The probabilistic sensitivity analysis demonstrated that standard therapy was more likely to be cost-effective compared with pembrolizumab at a WTP value of US$28 130/QALY. Results were robust across both univariate analysis and probabilistic sensitivity analysis.ConclusionsPembrolizumab is not likely to be a cost-effective strategy compared with SOC therapy in patients with platinum-resistant r/mHNSCC in China.Trial registration numberNCT02252042; Post-results.

scholarly journals Personality Traits Affect the Cost‐Effectiveness of Total Knee Arthroplasty

2021 ◽  
Author(s):  
Chao Chen ◽  
Ying‐ying Shi ◽  
Xiao An ◽  
Long Gong ◽  
Ming‐sheng Tan ◽  
...  
Keyword(s):  
Total Knee Arthroplasty ◽  
Cost Effectiveness ◽  
Personality Traits ◽  
Knee Arthroplasty ◽  
Total Knee ◽  
The Cost

scholarly journals Cost-utility analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

2021 ◽  
Author(s):  
Yu Kondo ◽  
Tomoya Tachi ◽  
Takayoshi Sakakibara ◽  
Jun Kato ◽  
Takahito Mizuno ◽  
...  
Keyword(s):  
Sensitivity Analysis ◽  
Cost Effectiveness ◽  
Probabilistic Sensitivity Analysis ◽  
Cost Effective ◽  
Japanese Patients ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Antiemetic Therapy ◽  
Utility Analysis ◽  
The Cost

Abstract Purpose Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy, consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy. Although olanzapine may be more economical than aprepitant or palonosetron, an adequate cost-efficacy analysis has not been conducted. We conducted a cost-utility analysis to evaluate the cost-effectiveness of olanzapine in four-drug antiemetic therapy among Japanese patients.Methods We simulated model patients treated with highly emetogenic cisplatin-containing chemotherapy and developed a decision-analytical model of patients receiving triple antiemetic therapy with or without olanzapine. The cost, probabilities, and incremental cost-effectiveness ratio (ICER) of each treatment were calculated from the perspective of the Japanese healthcare payer. The threshold ICER was set at 45,867 United States dollars (USD) (5 million Japanese yen) per quality-adjusted life-year (QALY). The probabilities, utility value, and other costs were obtained from published sources. The robustness of this model was validated by one-way sensitivity analysis and probabilistic sensitivity analysis.Results The calculated ICER was 5,156 USD/QALY, which was below the threshold. Under the set conditions, the probabilistic sensitivity analysis revealed a 100% probability that olanzapine was cost-effective. Based on the one-way sensitivity analysis, reducing the cost of olanzapine below 10.78 USD placed the ICER below the threshold. Conclusion Olanzapine was cost-effective in the four-drug antiemetic therapy for Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

scholarly journals Modelling the cost-effectiveness of total knee arthroplasty: A systematic review

2020 ◽  
Vol 22 ◽  
pp. 485-492
Author(s):  
Achi Kamaraj ◽  
Kendrick To ◽  
KT Matthew Seah ◽  
Wasim S. Khan
Keyword(s):  
Systematic Review ◽  
Total Knee Arthroplasty ◽  
Cost Effectiveness ◽  
Knee Arthroplasty ◽  
Total Knee ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document